Pay in 4 interest-free payments of $6.74 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
New Access Options : Alternatives like oral GLP-1s, direct-to-consumer programs, and compounded medications provide more affordable and accessible solutions for patients without insurance coverage
The FDA has not yet accepted the recommendations, and inclusion on a compounding list would not constitute FDA approval or establish efficacy, safety, quality, an accepted indication or a standard dose
Li X, Zhu Y, He H, et al
Using tirzepatide solely to treat Hashimoto's disease itself would be considered off-label and requires individualized assessment
US$ 22.18
US$ 25.57
US$ 20.56
US$ 26.64
US$ 23.27
US$ 20.17
